Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapy.
Necchi A, Giannatempo P, Paolini B, Lo Vullo S, Marongiu M, Farè E, Raggi D, Nicolai N, Piva L, Catanzaro M, Biasoni D, Torelli T, Stagni S, Maffezzini M, Gianni AM, De Braud F, Mariani L, Sonpavde G, Colecchia M, Salvioni R. Necchi A, et al. Among authors: mariani l. Clin Genitourin Cancer. 2015 Apr;13(2):171-7.e1. doi: 10.1016/j.clgc.2014.08.002. Epub 2014 Aug 8. Clin Genitourin Cancer. 2015. PMID: 25193365
Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.
Decensi A, Veronesi U, Miceli R, Johansson H, Mariani L, Camerini T, Di Mauro MG, Cavadini E, De Palo G, Costa A, Perloff M, Malone WF, Formelli F. Decensi A, et al. Among authors: mariani l. Clin Cancer Res. 2003 Oct 15;9(13):4722-9. Clin Cancer Res. 2003. PMID: 14581342 Clinical Trial.
Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma.
Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, Pinotti G, Bonetti A, Carreca I, Biasco G, Bonaglia L, Marini G, Iannelli A, Cortinovis D, Ferrario E, Beretta E, Lambiase A, Buzzoni R; Italian Trials in Medical Oncology (I.T.M.O.) Group. Bajetta E, et al. Among authors: mariani l. Cancer. 2004 Jan 15;100(2):279-87. doi: 10.1002/cncr.11910. Cancer. 2004. PMID: 14716761 Free article. Clinical Trial.
Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer.
Morabito A, Gattuso D, Stani SC, Fanelli M, Ferraù F, De Sio L, Castellana MA, Lorusso V, Priolo D, Vitale S, Sarmiento R, Lo Vullo S, Mariani L, Gasparini G. Morabito A, et al. Among authors: mariani l. Breast Cancer Res Treat. 2004 Aug;86(3):249-57. doi: 10.1023/B:BREA.0000036898.45123.e9. Breast Cancer Res Treat. 2004. PMID: 15567941 Clinical Trial.
The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates.
Gasparini G, Meo S, Comella G, Stani SC, Mariani L, Gamucci T, Avallone A, Lo Vullo S, Mansueto G, Bonginelli P, Gattuso D, Gion M. Gasparini G, et al. Among authors: mariani l. Cancer J. 2005 May-Jun;11(3):209-16. doi: 10.1097/00130404-200505000-00007. Cancer J. 2005. PMID: 16053664 Clinical Trial.
1,156 results